Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Inotrem (France)
Alternate names:
Inotrem,
Inotrem S.A.,
Inotrem SA
ROR:
02t4pph48
OpenAlex ID:
I4405271659
TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction
2015
·
Amir Boufenzer
, Jérémie Lemarié
, et al.
·
Circulation Research
·
164
Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis
2016
·
Jeremie Joffre
, Stephane Potteaux
, et al.
·
Journal of the American College of Cardiology
·
117
PDF
Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients
2022
·
Virginie Montiel
, Irina Lobysheva
, et al.
·
EBioMedicine
·
109
PDF
TREM-1 multimerization is essential for its activation on monocytes and neutrophils
2018
·
Kevin Carrasco
, Amir Boufenzer
, et al.
·
Cellular and Molecular Immunology
·
102
PDF
Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis
2021
·
Amir Boufenzer
, Kevin Carrasco
, et al.
·
Cellular and Molecular Immunology
·
92
PDF
TREM-1 orchestrates angiotensin II–induced monocyte trafficking and promotes experimental abdominal aortic aneurysm
2020
·
Marie Vandestienne
, Yujiao Zhang
, et al.
·
Journal of Clinical Investigation
·
92
PDF
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
2023
·
Bruno François
, Simon Lambden
, et al.
·
The Lancet Respiratory Medicine
·
88
PDF
sTREM-1 is a specific biomarker of TREM-1 pathway activation
2021
·
Lucie Jolly
, Kévin Carrasco
, et al.
·
Cellular and Molecular Immunology
·
75
PDF
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
2020
·
Bruno François
, Xavier Wittebole
, et al.
·
Intensive Care Medicine
·
73
Targeted endothelial gene deletion of triggering receptor expressed on myeloid cells-1 protects mice during septic shock
2018
·
Lucie Jolly
, Kevin Carrasco
, et al.
·
Cardiovascular Research
·
53
THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1
2024
·
Julie Giraud
, Domitille Chalopin
, et al.
·
Cell Reports
·
48
PDF
A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition
2018
·
Valerie Cuvier
, Ulrike Lorch
, et al.
·
British Journal of Clinical Pharmacology
·
45
Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19
2021
·
Aline H. de Nooijer
, Inge Grondman
, et al.
·
Bioscience Reports
·
37
PDF
The Triggering Receptor Expressed on Myeloid cells-1: A new player during acute myocardial infarction
2015
·
Lemarié Jérémie
, Boufenzer Amir
, et al.
·
Pharmacological Research
·
37
Triggering Receptor Expressed on Myeloid cells-1: a new player in platelet aggregation
2017
·
Lucie Jolly
, Jérémie Lemarié
, et al.
·
Thrombosis and Haemostasis
·
33
Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation
2019
·
Sébastien Gibot
, Lucie Jolly
, et al.
·
Frontiers in Immunology
·
30
PDF
Pharmacological Inhibition of The Triggering Receptor Expressed on Myeloid Cells-1 Limits Reperfusion Injury in a Porcine Model of Myocardial Infarction
2015
·
Jérémie Lemarié
, Amir Boufenzer
, et al.
·
ESC Heart Failure
·
25
PDF
Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study
2022
·
Melanie Dechamps
, Julien De Poortere
, et al.
·
Frontiers in Medicine
·
21
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial
2021
·
Bruno Francois
, Simon Lambden
, et al.
·
BMJ Open
·
21
PDF
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial
2023
·
Bruno François
, Simon Lambden
, et al.
·
EClinicalMedicine
·
17
PDF
One-week in vivo sustained release of a peptide formulated into in situ forming implants
2017
·
Marianne Parent
, Igor Clarot
, et al.
·
International Journal of Pharmaceutics
·
17
Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill
2023
·
Mélanie Dechamps
, Julien De Poortere
, et al.
·
International Journal of Molecular Sciences
·
16
PDF
Inhibition of triggering receptor expressed on myeloid cells‐1 impairs thrombin generation
2019
·
Elisa Di Pillo
, Kevin Carrasco
, et al.
·
Journal of Thrombosis and Haemostasis
·
13
PDF
Plasma and genetic determinants of soluble TREM-1 and major adverse cardiovascular events in a prospective cohort of acute myocardial infarction patients. Results from the FAST-MI 2010 study
2021
·
Hafid Ait-Oufella
, Mengyao Yu
, et al.
·
International Journal of Cardiology
·
11
PDF
Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients
2023
·
Sébastien Gibot
, Thomas Lafon
, et al.
·
Intensive Care Medicine Experimental
·
10
PDF
Show more works
View as search
Works count:
39
Citation count:
6,062
Year
Topic
Type
